Rua Bioscience is trading 7.69% down now at NZD 0.04, with the decline appearing consistent with weaker biotech sentiment; no company-specific announcement or clear catalyst was identified for September 15, 2026.
- The XBI biotech ETF fell 2.11% following disappointing drug-trial news and broader pressure on commercial-stage biotech stocks.
- Wider risk-off conditions, including higher yields and weaker major indexes, likely added pressure.